Description
Launch of the EASL–Lancet Commission 2.0
From Evidence to Impact: Implementing Sustainable Liver Health in Europe
We are pleased to invite you to the official launch of the EASL–Lancet Commission 2.0, a major initiative aimed at advancing liver health across Europe.
The Commission presents updated evidence and actionable policy recommendations to reduce the burden of liver disease and strengthen prevention, early detection, and care.
Under the title “From Evidence to Impact: Implementing Sustainable Liver Health in Europe,” this event will bring together policymakers, health experts, researchers, and stakeholders to explore how scientific evidence can be translated into meaningful policy and sustainable action for liver health across Europe.
Event Details
Event: Launch of the EASL–Lancet Commission 2.0
Title: From Evidence to Impact: Implementing Sustainable Liver Health in Europe
📅 Date: 30 April 2026
🕒 Programme:
- 10:30 — Registration and coffee
- 11:00–13:00 — Event programme
- 13:00 onwards — Complimentary lunch
📍 Location: TownHall Europe, Square de Meeûs 5–6, Brussels
📍 Online: If you are unable to attend in person, you may join the event online.
Programme
This event will bring together policymakers, clinicians, researchers, economists, and civil society to translate recommendations into action at EU and national levels.
| Topic | Speaker |
| Introductory Statements | Debbie Shawcross, EASL Secretary General |
| Keynote Address | Hans Kluge, WHO Europe Regional Director |
| Making a case for Europe – Why a European Lancet Liver Commission? | Richard Horton, Editor-in-Chief The Lancet |
| Overview of the EASL- Lancet Commission Recommendations | Tom H. Karlsen, Co-Chair EASL-Lancet Commission |
| Presentations from Commissioners | |
| European liver health in numbers | Sharon Hutchinson, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK |
| Alcohol control: lessons from tobacco | Harry Rutter, Department of Social and Policy Sciences, University of Bath, UK |
| European health policy fragmentation: a medicines pricing transparency case | Francesco Negro, Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland |
| Multimorbidity-oriented pathways of liver care | Aleksander Krag, Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Denmark |
| Economic perspectives on liver disease in Europe | Michele Cecchini, Health Division, Organisation of Economic Co-operation and Development, OECD |
| Panel Discussion: | |
| Moderators:
Shira Zelber-Sagi, Yes EASL Public Health Councillor Sabine Kleinert, Yes The Lancet
|
· Francesco Giorgino, EASD President
|
| Q&A from the Audience | |
| Perspectives and Momentum of Related to the Lancet Commissions | Sabine Kleinert, The Lancet |
| Closing Remarks | Patrizia Burra, Gastroenterology, Department of Surgery, Padua University Hospital, Italy |
We look forward to welcoming you to this important discussion on the future of liver health in Europe.